RxDoctor Payments Data

Rumana Siddiqui, MD

Family Medicine · Arlington Heights, ILNPI 1770777377

Payments from drug & device makers

$8,672in general payments, 2019–2025

Across 393 payments — averaging $22.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Lilly USA, LLC$1K
  • Amgen$729
  • Johnson & Johnson$664
  • Bayer$604
  • Novo Nordisk$494
  • plus $4K from 35 others

What the payments were for

  • Food & beverage$8,44197%
  • Education$2313%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,672 in reported general payments places this provider in the 95th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$427,517
Medicare patients
319
Services billed
3,674

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin274$229,030
EliquisApixaban177$109,095
JanuviaSitagliptin Phosphate72$61,521
FarxigaDapagliflozin Propanediol56$47,288
TradjentaLinagliptin44$38,678
MounjaroTirzepatide27$28,430
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$26,441
Breztri AerosphereBudesonide/Glycopyr/Formoterol38$23,840
EntrestoSacubitril/Valsartan27$20,893
MyrbetriqMirabegron38$20,605
OzempicSemaglutide12$18,951
GemtesaVibegron26$14,416
LinzessLinaclotide15$13,228
CreonLipase/Protease/Amylase11$11,060
Breo ElliptaFluticasone/Vilanterol25$10,106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$384$267,708318 claims
PfizerEliquis$387$109,095177 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,270$71,12894 claims
MerckJanuvia$90$61,52172 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$92$39,71673 claims
Lilly USA, LLCMounjaro$1,162$28,43027 claims
NovartisEntresto$186$20,89327 claims
Astellas Pharma US IncMyrbetriq$165$20,60538 claims
Novo NordiskOzempic$494$18,95112 claims
Sumitomo Pharma America, Inc.Gemtesa$243$14,41626 claims
Johnson & JohnsonXarelto$664$8,84218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in Arlington Heights

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →